Pharmacy Benefit Managers Face Federal Pricing Scrutiny

The Middlemen Under the Microscope

Pharmacy benefit managers – the companies that sit between drug manufacturers, insurers, and patients – have long operated in the background of American healthcare. They negotiate drug prices, manage formularies, and process claims for millions of Americans. For years, that opaque position gave them enormous pricing power and very little public accountability. That era of comfortable obscurity is ending fast.

Federal regulators and lawmakers on both sides of the aisle are now pressing hard on how PBMs set drug prices, what they keep from those negotiations, and whether their business model systematically inflates costs for the very patients it claims to serve. The scrutiny arrives at a moment when prescription drug affordability has become one of the few genuinely bipartisan political issues in Washington.

What PBMs Actually Do – and Why It Matters

Three companies – CVS Caremark, Express Scripts, and OptumRx – control the vast majority of the U.S. PBM market, processing prescriptions for hundreds of millions of Americans. Their core function sounds administrative: they manage drug benefit programs for employers, insurers, and government programs. In practice, they wield enormous influence over which drugs get covered, at what cost, and how much pharmacies get reimbursed for dispensing them.

The central controversy involves a practice called spread pricing, where a PBM charges an insurer more for a drug than it pays the pharmacy, pocketing the difference without disclosure. A related issue involves rebates – payments drug manufacturers make to PBMs in exchange for preferred placement on formularies. Critics argue these rebates incentivize PBMs to favor high-list-price drugs over cheaper alternatives, because a larger rebate from an expensive drug can be more lucrative than simply choosing the lowest-cost option for patients.

The financial architecture here is genuinely difficult to follow, and that is not accidental. PBMs have historically resisted disclosure requirements, arguing that transparency would undermine their negotiating leverage with manufacturers. That argument has grown harder to defend as evidence mounts that the opacity benefits PBM margins far more than patient costs.

Washington Moves In

The Federal Trade Commission launched an investigation into PBM practices in 2022, and its subsequent interim report was notably pointed in its criticism. The agency found that the largest PBMs had used their market position to disadvantage independent pharmacies, steer patients toward affiliated mail-order and specialty pharmacies they own, and engage in pricing practices that raised serious questions about conflicts of interest. The FTC stopped well short of formal enforcement action in that report, but the direction of travel was clear.

Congressional attention has followed. Multiple bills targeting PBM transparency and spread pricing have moved through committee stages in recent sessions, with proposals ranging from mandatory disclosure of rebate arrangements to outright bans on spread pricing in Medicaid programs. The challenge in passing comprehensive reform remains the lobbying infrastructure PBMs have built – the industry spends heavily in Washington, and the three dominant players are subsidiaries of massive healthcare conglomerates with diversified political relationships.

The Cost Argument – and Its Complications

The core claim PBMs make in their own defense is that they save the healthcare system money by negotiating discounts manufacturers would never offer to individual insurers or employers. There is real substance to this argument. The negotiated rebates PBMs extract from pharmaceutical companies do reduce net drug spending in some measurable ways, and smaller employers would have virtually no leverage in direct negotiations with large drug makers. The question is not whether PBMs generate any savings, but whether those savings reach patients or get absorbed further up the chain.

The structure of most PBM contracts determines who captures the benefit. When an employer or insurer negotiates a contract that passes rebates through to the plan, patients can see lower premiums or cost-sharing. When PBMs retain a portion of rebates as additional compensation – a common arrangement – the savings effectively disappear from the patient-facing side of the equation. The variation in contract structures across thousands of employer plans makes it nearly impossible to assess the net impact without the kind of data disclosure PBMs have consistently resisted.

Independent pharmacies have pressed this case loudly and with growing political success. Many smaller pharmacies have documented situations where PBM reimbursement rates fall below their acquisition cost for certain drugs – meaning they lose money on the transaction. The National Community Pharmacists Association has brought these cases repeatedly to Congress, and the FTC’s interim report corroborated many of the core complaints. Several states have already passed laws restricting below-cost reimbursements, though enforcement remains inconsistent.

The most contentious near-term question involves insulin and other high-profile drugs where the gap between list price and net price after rebates has become a public flash point. When a drug has a list price of several hundred dollars but a net price after rebates far below that, the PBM model gets credit for the discount while patients who lack insurance or face high deductibles pay something close to the list price. This mismatch – where the rebate system produces savings that bypass the patient at the point of sale – has become the clearest illustration of what reform advocates argue is a structural flaw rather than a marginal inefficiency. Whether Congress can translate that specific grievance into workable legislation, given the complexity of the underlying contracts and the political durability of the industry’s lobbying operation, is a question that current bill counts in both chambers do not yet answer.